| $376M | ||
| $350M | ||
| $215M | ||
| $107M | ||
| $100M | ||
| $99M |
Buys | $0 | 0 | 0 |
Sells | $0 | 6 | 100 |
| FMR LLC | See Remark 1 | 0 | $0 | 6 | $0 | $0 |
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
Over the last 12 months, insiders at Structure Therapeutics Inc. have bought $0 and sold $0 worth of Structure Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Structure Therapeutics Inc. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-04-14 | Sale | FMR LLC | See Remark 1 | 17,452 – | $0 | $0 | -24.80% | |
| 2026-01-15 | Sale | FMR LLC | See Remark 1 | 17,452 – | $0 | $0 | -38.97% | |
| 2025-12-08 | Sale | FMR LLC | See Remark 1 | 32,720 – | $0 | $0 | -19.26% | |
| 2025-12-08 | Sale | FMR LLC | See Remark 1 | 35,501 – | $0 | $0 | -19.26% | |
| 2025-12-08 | Sale | FMR LLC | See Remark 1 | 52,356 – | $0 | $0 | -19.26% | |
| 2025-07-30 | Sale | FMR LLC | See Remark 1 | 26,310 – | $0 | $0 | +123.72% | |
| 2025-02-06 | Sale | FMR LLC | See Remark 1 | 41 – | $0 | $0 | -20.92% | |
| 2024-06-10 | Sale | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | 185,000 – | $0 | $0 | -39.09% | |
| 2024-06-03 | Sale | Lin Xichen | CHIEF SCIENTIFIC OFFICER | 35,400 – | $0 | $0 | -36.86% |
| Increased Positions | 124 | +62.31% | 20M | +35.41% |
| Decreased Positions | 93 | -46.73% | 11M | -19.72% |
| New Positions | 71 | New | 6M | New |
| Sold Out Positions | 29 | Sold Out | 4M | Sold Out |
| Total Postitions | 230 | +15.58% | 66M | +15.69% |
| Wellington Management Group Llp | $387,547.00 | 2.75% | 5.69M | -1M | -17.26% | 2025-09-30 |
| Fmr Llc | $357,655.00 | 2.54% | 5.25M | +335,403 | +6.82% | 2025-09-30 |
| Avoro Capital Advisors Llc | $351,196.00 | 2.49% | 5.16M | +5M | New | 2025-09-30 |
| Janus Henderson Group Plc | $303,054.00 | 2.15% | 4.45M | -124,180 | -2.72% | 2025-09-30 |
| Deep Track Capital, Lp | $287,181.00 | 2.04% | 4.22M | -918,106 | -17.88% | 2025-09-30 |
| Bvf Inc/Il | $218,251.00 | 1.55% | 3.2M | +1M | +80.87% | 2025-09-30 |
| Baker Bros. Advisors Lp | $106,002.00 | 0.75% | 1.56M | -952,658 | -37.97% | 2025-09-30 |
| Casdin Capital, Llc | $105,927.00 | 0.75% | 1.55M | +330,000 | +26.94% | 2025-09-30 |
| Ra Capital Management, L.P. | $103,367.00 | 0.73% | 1.52M | 0 | 0% | 2025-09-30 |
| Millennium Management Llc | $86,822.00 | 0.62% | 1.27M | +54,496 | +4.47% | 2025-09-30 |